Search
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Mixtures: PHESGO® 600MG/600MG, PHESGO® 600MG/600MGCategories: Receptor, ErbB-2, antagonists & inhibitors, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsOmapatrilat
go.drugbank.com/drugs/DB00886ExperimentalThis drug from BMS was not approved by the FDA due to angioedema safety concerns. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).
Categories: Agents Acting on the Renin-Angiotensin System, Heterocyclic Compounds, 1-RingSulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Synonyms: 4-Sulfanilamido-5,6-dimethoxypyrimidineLofentanil
go.drugbank.com/drugs/DB09174ExperimentalIllicitIt displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more potent than this drug. … Lofentanil is an analog of fentanyl and is one of the most potent opioids available today.
Categories: Heterocyclic Compounds, 1-Ring, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalAs a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesNaftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
International brands: A MeiProducts: EXODERIL %1 KREM, 15 G, EXODERIL %1 KREM, 30 GDiphenidol
go.drugbank.com/drugs/DB01231ApprovedWithdrawnDiphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.
Categories: Heterocyclic Compounds, 1-RingSynonyms: Diphenyl(3-(1-piperidyl)propyl)carbinol, alpha,alpha-Diphenyl-1-piperidinebutanolEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalEfinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. … It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanolVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinoneAlglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnThe modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues. … Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.